Singapore markets close in 2 hours 6 minutes

Coya Therapeutics, Inc. (COYA)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
8.67-0.38 (-4.20%)
At close: 04:00PM EDT
8.87 +0.20 (+2.31%)
After hours: 06:40PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close9.05
Open9.00
Bid8.58 x 100
Ask8.90 x 100
Day's range8.61 - 9.11
52-week range3.21 - 10.69
Volume44,878
Avg. volume101,137
Market cap126.601M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Business Wire

    Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium

    HOUSTON, April 26, 2024--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya’s Scientific Advisory Board, and Dr. David Beers, Ph.D., Associate Research Professor of Neurology, Houston Methodist Hospital (HMH), will present biomarker data today as part of a presentation at the 2nd Annual Johnson Center Symposium

  • Business Wire

    Coya Therapeutics to Participate in the Mizuho Neuroscience Summit

    HOUSTON, April 22, 2024--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer and Chairman of the Board Howard Berman, Ph.D., and Chief Business Development Officer Arun Swaminathan, Ph.D., will participate in the Mizuho Neuroscience Summit being held May 20 – 21 at the Boston Harbor Hotel. Drs. Berman and Swaminathan will also be

  • Business Wire

    Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit

    HOUSTON, April 18, 2024--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that President and Chief Medical Officer Dr. Fred Grossman, D.O., FAPA will participate in the 3rd Annual ALS Drug Development Summit being held May 21 – 23 at the Hyatt Regency in Boston.